S&P Futures
4,214.75 +5.00 (+0.12%) Dow Futures
33,335.00 +31.00 (+0.09%) Nasdaq Futures
13,335.75 +24.50 (+0.18%) Russell 2000 Futures
1,978.70 +2.40 (+0.12%) Crude Oil
94.13 -0.21 (-0.22%) Gold
1,803.80 -3.40 (-0.19%)
Aziyo Biologics, Inc. (AZYO)
Chart Events
Performance Outlook
| Previous Close | 6.45 |
| Open | 6.45 |
| Bid | 7.00 x 1100 |
| Ask | 12.02 x 900 |
| Day's Range | 6.91 - 7.06 |
| 52 Week Range | 4.10 - 9.76 |
| Volume | |
| Avg. Volume | 4,941 |
| Market Cap | 93.69M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.10 |
| Earnings Date | Feb 28, 2022 - Mar 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.50 |
- GlobeNewswire
Aziyo Biologics Announces Second Quarter 2022 Financial Results and Recent Business Achievements, Including Robust Revenue Growth and Strengthened Balance Sheet
SILVER SPRING, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today provided a business update and reported financial results for the second quarter June 30, 2022. Recent Highlights Total net sales of $12.6 million, a 3.9% increase compared to $12.2 million in the second quarter of 2021 Net sales growth from existing products of 20.3%, after excluding Q2 2021 sales of discontinued product FiberCel Co-founder and boar
- American City Business Journals
Silver Spring biotech names new CEO
The regenerative medicine company has named Randy Mills, one of its co-founders, as its new president and CEO. Lloyd “is still with Aziyo and is actively assisting with that transition,” a company spokesperson confirmed Thursday to the Washington Business Journal. Since then, Aziyo co-founder Kevin Rankin, co-founder and partner of New York investment fund HighCape Capital, has also been the Maryland biotech’s executive chairman.
- GlobeNewswire
Aziyo Biologics Announces $25 Million Loan Facility with SWK Holdings
Provides Additional Working Capital to Further Fund Growth InitiativesSILVER SPRING, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (the “Company”), a commercial-stage regenerative medicine company announced today that it has entered into a $25 million credit facility from SWK Holdings Corporation. The new credit facility provides for an initial term loan of $21 million that the Company intends to use to fund its ongoing commercial and product development initiatives
